+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Hematologic effects of recombinant human granulocyte colony-stimulating factor in patients with malignancy



Hematologic effects of recombinant human granulocyte colony-stimulating factor in patients with malignancy



Blood 74(8): 2644-2651



The effect of recombinant human granulocyte colony-stimulating factor (G-CSF) on hematologic parameters was evaluated in a phase I clinical study in 18 patients with advanced malignancy. G-CSF was administered once daily as a 30-minute infusion for 14 days; three patients each were treated at increasing dose levels of 1, 3, 10, 30, and 60 micrograms kg-1 day-1. A transient decrease in neutrophil and monocyte counts was observed immediately after the G-CSF infusion, followed by a dose-dependent increase of up to 15-fold. G-CSF-induced neutrophils exhibited an increased O2- radical production, and serum levels of enzymes related to granulocyte turnover, including lysozyme and elastase, were markedly elevated during therapy. A dose-dependent depression of platelet counts occurred in the second third of the treatment course, followed by a spontaneous recovery despite continuing therapy. G-CSF was well-tolerated; minor to moderate bone pain was the most common side effect. The primary course of the malignant diseases studied was not significantly altered. G-CSF appears to be an appropriate means to selectively increase the number of functionally competent polymorphonuclear phagocytes.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 040260951

Download citation: RISBibTeXText

PMID: 2479425


Related references

Hematologic effects of recombinant human granulocyte macrophage colony stimulating factor and interleukin-6 administered to patients with malignancy. Blood 84(10 Suppl. 1): 598A, 1994

Effects of bacterially synthesized recombinant human granulocyte macrophage colony stimulating factor in patients with advanced malignancy. Annals of Internal Medicine 110(5): 357-364, 1989

Effect of recombinant human granulocyte colony-stimulating factor (G-CSF) in the treatment of Pseudomonas aeruginosa bacteremia complicating hematologic malignancy--a preliminary study. Kansenshogaku Zasshi. Journal of the Japanese Association for Infectious Diseases 66(1): 76-80, 1992

Acute and chronic hematologic effects of recombinant human granulocyte colony stimulating factor. Laboratory Investigation 60(1): 99A, 1989

Effects of recombinant human granulocyte colony-stimulating factor on the hematologic recovery and survival of irradiated mice. Blood 76(3): 445-449, 1990

Interdependence of the radioprotective effects of human recombinant interleukin 1 alpha tumor necrosis factor alpha granulocyte colony stimulating factor and murine recombinant granulocyte macrophage colony stimulating factor. Journal of Immunology 140(1): 108-111, 1988

Hematologic effects of subcutaneous administration of recombinant human granulocyte colony-stimulating factor (filgrastim) in healthy alpacas. American Journal of Veterinary Research 69(6): 770-776, 2008

Recombinant human granulocyte-macrophage colony-stimulating factor in patients with advanced malignancy: a phase Ib trial. Journal of the National Cancer Institute 82(8): 697-703, 1990

Phase i ii study of recombinant human granulocyte macrophage colony stimulating factor in patients with advanced malignancy. Acta Haematologica 87(1-2): 22-28, 1992

Phase I study of recombinant human granulocyte-macrophage colony-stimulating factor in patients with advanced malignancy. Bulletin du Cancer (Paris) 80(5): 418-430, 1993

The effects of recombinant human granulocyte macrophage colony stimulating factor gm csf granulocyte colony stimulating factor g csf and interleukin 3 il 3 on human neutrophil pmn oxidative activity and migration. Clinical Research 38(2): 458A, 1990

Effects of recombinant human granulocyte colony stimulating factor and granulocyte-monocyte colony stimulating factor on in vitro hemopoiesis in the myelodysplastic syndromes. Leukemia 4(3): 193-202, 1990

Dose escalation study of recombinant human granulocyte-colony-stimulating factor (KRN8601) in patients with advanced malignancy. Cancer Research 49(18): 5221-5224, 1989

Hematopoietic responses in patients with advanced malignancy treated with recombinant human granulocyte-macrophage colony-stimulating factor. Journal of Clinical Oncology 7(2): 159-167, 1989